Cellogen Therapeutics secures ₹20 crore in funding led by Kotak Alternate Asset Managers.
The biotech startup is developing indigenous, next-generation CAR-T cell and gene therapies.
Global CAR-T treatments cost up to ₹4 crore; Cellogen aims to slash this cost by nearly 90% for Indian patients.
The capital will accelerate clinical trials and strengthen GMP-compliant manufacturing capabilities.
Read the full story on StartupFox